Insider Buying: Boston Scientific (NYSE:BSX) Director Purchases $99,939.00 in Stock

Boston Scientific Corporation (NYSE:BSX) Director David Habiger bought 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Boston Scientific Price Performance

BSX opened at $49.35 on Monday. The stock has a fifty day moving average of $45.75 and a 200-day moving average of $60.54. The firm has a market capitalization of $71.53 billion, a P/E ratio of 19.98, a PEG ratio of 1.08 and a beta of 0.56. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its board has authorized a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its shares are undervalued.

Institutional Trading of Boston Scientific

Several large investors have recently added to or reduced their stakes in the company. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. Swiss RE Ltd. bought a new position in Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC acquired a new position in Boston Scientific in the fourth quarter worth $26,000. Sfam LLC acquired a new position in Boston Scientific in the fourth quarter worth $29,000. Finally, Eagle Bay Advisors LLC bought a new stake in shares of Boston Scientific during the fourth quarter worth $30,000. 89.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on BSX shares. Needham & Company LLC dropped their price target on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Mizuho decreased their price target on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Daiwa Securities Group downgraded shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Barclays lowered their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. Finally, Jefferies Financial Group reduced their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, June 24th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.